MMD

Across TCGA pan-cancer cohorts, MMD mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MMD data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MMD mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MMD expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

HNSC, LUAD, and PDAC are the cancer types where MMD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.802	0.449	.008	10	view →
LUAD	DFS	Median	All	0.750	0.994	.033	6	view →
PDAC	DFS	Quartile	II,III,IV	0.980	0.629	.020	6	view →
UCEC	DFS	Median	All	0.958	0.836	.030	2	view →
GBM	DFS	Tertile	All	0.612	0.915	.025	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MMD–HNSC (DFS)

Open the HNSC breakdown →